U.S. Patent Granted for Stenoparib DRP® Diagnostic, Securing Exclusivity Until 2042
ALLR sits 73% above its 52-week low of $0.769 on light trading volume (0.4× avg).
Summary
Allarity Therapeutics announced the grant of a key U.S. patent for its stenoparib DRP® companion diagnostic, securing exclusivity until April 2042. This follows the Notice of Allowance from the USPTO, which the company announced in an 8-K filing on April 28th. The patent is a critical step, establishing a long-term intellectual property foundation for stenoparib and its patient-selection approach in ovarian cancer. For a clinical-stage biotech, this significantly de-risks the future commercialization pathway of a lead asset.
At the time of this announcement, ALLR was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.7M. The 52-week trading range was $0.77 to $2.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.